Serum diagnosis of diffuse large B-cell lymphomas and further identification of response to therapy using SELDI-TOF-MS and tree analysis patterning

BMC Cancer

Volumn 7, Issue , 2007, Pages

  Zhang, Xing ^a   Wang, Bo ^a   Zhang, Xiao Shi ^a   Li, Zhi Ming ^a   Guan, Zhong Zhen ^a   Jiang, Wen Qi ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PLASMA PROTEIN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BLOOD ANALYSIS; CANCER STAGING; COMPUTER PROGRAM; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TREATMENT RESPONSE; B LYMPHOCYTE; BLOOD; DECISION TREE; GENETIC MARKER; MASS SPECTROMETRY; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PREDICTION AND FORECASTING; PROTEIN MICROARRAY; REFERENCE VALUE; REPRODUCIBILITY; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; AGED; B-LYMPHOCYTES; BLOOD PROTEINS; COMBINED MODALITY THERAPY; DECISION TREES; GENETIC MARKERS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 39449122639     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-7-235     Document Type: Article

References (35)

1. Wu G Keating A Biomarkers of potential prognostic significance in diffuse large B-cell lymphoma Cancer 2006, 106(2):247-257. 10.1002/ cncr.21586 16342164
2. Abramson JS Shipp MA Advances in the biology and therapy of diffuse large B-cell lymphoma: Moving toward a molecularly targeted approach Blood 2005, 106(4):1164-1174. 10.1182/blood-2005-02-0687 15855278
3. Petricoin EF 3rd Ornstein DK Paweletz CP Ardekani A Hackett PS Hitt BA Velassco A Trucco C Wiegand L Wood K Simone CB Levine PJ Linehan WM Emmert-Buck MR Steinberg SM Kohn EC Liotta LA Serum proteomic patterns for detection of prostate cancer J Natl Cancer Inst 2002, 94(20):1576-1578. 12381711
4. Petricoin EF Ardekani AM Hitt BA Levine PJ Fusaro VA Steinberg SM Mills GB Simone C Fishman DA Kohn EC Liotta LA Use of proteomic patterns in serum to identify ovarian cancer Lancet 2002, 359(9306):572-577. 10.1016/ S0140-6736(02)07746-2 11867112
5. Walsh PC Serum proteomic patterns for detection of prostate cancer J Urol 2003, 169(4):15902. 10.1097/01.ju.0000054024.38754.f0
6. Banez LL Prasanna P Sun L Ali A Zou Z Adam BL McLeod DG Moul JW Srivastava S Diagnostic potential of serum proteomic patterns in prostate cancer J Urol 2003, 170(2 Pt 1):442-446. 10.1097/ 01.ju.0000069431.95404.56 12853795
7. Adam BL Qu Y Davis JW Ward MD Clements MA Cazares LH Semmes OJ Schellhammer PF Yasui Y Feng Z Wright GL Jr. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men Cancer Res 2002, 62(13):3609-3614. 12097261
8. Wright GL Jr. SELDI proteinchip MS: A platform for biomarker discovery and cancer diagnosis Expert Rev Mol Diagn 2002, 2(6):549-563. 10.1586/ 14737159.2.6.549 12465452
9. Wulfkuhle JD McLean KC Paweletz CP Sgroi DC Trock BJ Steeg PS Petricoin EF 3rd New approaches to proteomic analysis of breast cancer Proteomics 2001, 1(10):1205-1215. 10.1002/ 1615-9861(200110)1:10<1205::AID-PROT1205<3.0.CO;2-X 11721633
10. Paweletz CP Trock B Pennanen M Tsangaris T Magnant C Liotta LA Petricoin EF 3rd Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: Potential for new biomarkers to aid in the diagnosis of breast cancer Dis Markers 2001, 17(4):301-307. 11790897
11. Miguet L Bogumil R Decloquement P Herbrecht R Potier N Mauvieux L Van Dorsselaer A Discovery and identification of potential biomarkers in a prospective study of chronic lymphoid malignancies using SELDI-TOF-MS J Proteome Res 2006, 5(9):2258-2269. 10.1021/pr060058y 16944938
12. Lin Z Jenson SD Lim MS Elenitoba-Johnson KS Application of SELDI-TOF mass spectrometry for the identification of differentially expressed proteins in transformed follicular lymphoma Mod Pathol 2004, 17(6):670-678. 10.1038/modpathol.3800100 15098007
13. Lossos IS Molecular pathogenesis of diffuse large B-cell lymphoma J Clin Oncol 2005, 23(26):6351-6357. 10.1200/JCO.2005.05.012 16155019
14. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project N Engl J Med 1993, 329(14):987-994. 10.1056/NEJM199309303291402 8141877
15. Shipp MA Ross KN Tamayo P Weng AP Kutok JL Aguiar RC Gaasenbeek M Angelo M Reich M Pinkus GS Ray TS Koval MA Last KW Norton A Lister TA Mesirov J Neuberg DS Lander ES Aster JC Golub TR Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning Nat Med 2002, 8(1):68-74. 10.1038/nm0102-68 11786909
16. Zhang H Kong B Qu X Jia L Deng B Yang Q Biomarker discovery for ovarian cancer using SELDI-TOF-MS Gynecol Oncol 2006, 102(1):61-66. 10.1016/ j.ygyno.2005.11.029 16403569
17. Issaq HJ Veenstra TD Conrads TP Felschow D The SELDI-TOF MS approach to proteomics: Protein profiling and biomarker identification Biochem Biophys Res Commun 2002, 292(3):587-592. 10.1006/bbrc.2002.6678 11922607
18. Breiman L Random Forests. Technical Report 567. Berkeley, CA:, Department of Statistics, University of California. 1999
19. Breiman L Friedman J Olshen R Stone C Steinberg D P. C CART: Classificationand Regression Trees. Stanford, CA, SalfordSystem. 1995
20. Vlahou A Giannopoulos A Gregory BW Manousakas T Kondylis FI Wilson LL Schellhammer PF Wright GL Jr. Semmes OJ Protein profiling in urine for the diagnosis of bladder cancer Clin Chem 2004, 50(8):1438-1441. 10.1373/ clinchem.2003.028035 15277356
21. Holterman DA Diaz JI Blackmore PF Davis JW Schellhammer PF Corica A Semmes OJ Vlahou A Overexpression of alpha-defensin is associated with bladder cancer invasiveness Urol Oncol 2006, 24(2):97-108. 16520271
22. Vlahou A Schellhammer PF Mendrinos S Patel K Kondylis FI Gong L Nasim S Wright Jr GL Jr. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine Am J Pathol 2001, 158(4):1491-1502. 1891900 11290567
23. Lossos IS Morgensztern D Prognostic biomarkers in diffuse large B-cell lymphoma J Clin Oncol 2006, 24(6):995-1007. 10.1200/JCO.2005.02.4786 16418498
24. Wilder RB Rodriguez MA Medeiros LJ Tucker SL Ha CS Romaguera JE Pro B Hess MA Cabanillas F Cox JD International prognostic index-based outcomes for diffuse large B-cell lymphomas Cancer 2002, 94(12):3083-3088. 10.1002/cncr.10583 12115338
25. Diamandis EP Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: Opportunities and potential limitations Mol Cell Proteomics 2004, 3(4):367-378. 10.1074/mcp.R400007-MCP200 14990683
26. Diamandis EP Serum proteomic profiling by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry for cancer diagnosis: Next steps Cancer Res 2006, 66(11):5540-5541. 10.1158/ 0008-5472.CAN-05-4503 16740686
27. Baggerly KA Morris JS Edmonson SR Coombes KR Signal in noise: Evaluating reported reproducibility of serum proteomic tests for ovarian cancer J Natl Cancer Inst 2005, 97(4):307-309. 15713966
28. Diamandis EP Re: Serum proteomic patterns for detection of prostate cancer J Natl Cancer Inst 2003, 95(6):489-90; author reply 490-1 12644546
29. Diamandis EP Analysis of serum proteomic patterns for early cancer diagnosis: Drawing attention to potential problems J Natl Cancer Inst 2004, 96(5):353-356. 14996856
30. Sorace JM Zhan M A data review and re-assessment of ovarian cancer serum proteomic profiling BMC Bioinformatics 2003, 4:24. 165662 12795817 10.1186/1471-2105-4-24
31. Baggerly KA Morris JS Coombes KR Reproducibility of SELDI-TOF protein patterns in serum: Comparing datasets from different experiments Bioinformatics 2004, 20(5):777-785. 10.1093/bioinformatics/btg484 14751995
32. Marshall J Kupchak P Zhu W Yantha J Vrees T Furesz S Jacks K Smith C Kireeva I Zhang R Takahashi M Stanton E Jackowski G Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction J Proteome Res 2003, 2(4):361-372. 10.1021/pr030003l 12938926
33. van der Merwe DE Oikonomopoulou K Marshall J Diamandis EP Mass spectrometry: Uncovering the cancer proteome for diagnostics Adv Cancer Res 2007, 96:23-50. 10.1016/S0065-230X(06)96002-3 17161675
34. Semmes OJ Feng Z Adam BL Banez LL Bigbee WL Campos D Cazares LH Chan DW Grizzle WE Izbicka E Kagan J Malik G McLerran D Moul JW Partin A Prasanna P Rosenzweig J Sokoll LJ Srivastava S Srivastava S Thompson I Welsh MJ White N Winget M Yasui Y Zhang Z Zhu L Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility Clin Chem 2005, 51(1):102-112. 10.1373/clinchem.2004.038950 15613711
35. Hong H Dragan Y Epstein J Teitel C Chen B Xie Q Fang H Shi L Perkins R Tong W Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS) BMC Bioinformatics 2005, 6 Suppl 2:S5. 1637033 16026602 10.1186/1471-2105-6-S2-S5